Cardeas Pharma Corporation
Records under this name other than patents Cardeas Pharma Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cardeas Pharma Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,526,695 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,696 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,697 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,526,698 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Dec 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2024 | From the USPTO record |
| US 9,486,462 | Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Formerly held Lapsed on the fee record Ended Nov 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2024 | From the USPTO record |
| US 10,471,083 | Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Nov 12, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 12, 2023 | From the USPTO record |
| US 10,406,171 | Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Lapsed on the fee record Ended Sep 10, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 10, 2023 | From the USPTO record |
| US 8,826,904 | Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Sep 9, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 9, 2022 | From the USPTO record |
| US 8,820,323 | Methods to administer formulations of aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Sep 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2022 | From the USPTO record |
| US 8,636,983 | Aminoglycoside and fosfomycin combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis Formerly held Lapsed on the fee record Ended Jan 28, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 28, 2018 | From the USPTO record |